Leonardo Mirandola, PhD
Chief Technology Officer
Leonardo Mirandola is a biotechnology executive and translational scientist with more than 15 years of leadership experience advancing cell and gene therapies, immunotherapies, and gene therapy programs from discovery through clinical development. As Chief Technology Officer of Vision BioSciences, he leads the company’s technical development strategy, guiding its regenerative therapy programs for maculopathies toward IND readiness and beyond.
Prior to joining Vision BioSciences, Leo served as Chief Scientific Officer and interim Chief Operating Officer of a NASDAQ-listed clinical-stage biopharmaceutical company, where he led the development of an allogeneic γδ T-cell therapy that achieved FDA Fast Track Designation. He architected an AI-driven platform for CAR-T target discovery based on tumor-specific splice variants, advanced multiple cell therapy candidates into Phase 1 trials, and oversaw the implementation of a fully cGMP-compliant manufacturing, QA, and QC framework.
He is an inventor on multiple international patent applications spanning engineered immune receptors, manufacturing processes, and antigen discovery technologies, and has secured non-dilutive funding through partnerships with leading academic medical centers. He serves as Associate Editor for Frontiers in Immunology and has authored more than 50 peer-reviewed publications and book chapters.
He holds a Ph.D. in Molecular Medicine and an M.S. in Medical Biotechnology from the University of Milano, Italy.
